Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig vs Dara-CyBorD in Newly Diagnosed AL Amyloidosis
NCT07793422Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Primary completion
- Dec 2034
01
Overview
A Phase 3 trial of etentamig in amyloid light chain amyloidosis, sponsored by AbbVie Inc.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
etentamig
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07793422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793422.